R&D News | pharmaphorum

News

Seagen posts breast cancer win ahead of Pfizer takeover

The combination of two HER2-targeting drugs – Seagen's oral Tukysa and Roche's intravenous antibody-drug conjugate (ADC) Kadcyla – has shown a benefit over Kadcyla alone a

News

Abcuro raises $155m for KLRG1 drug trial

Abcuro has raised $155 million in an oversubscribed second financing round that will fund its phase 2/3 trial of lead drug ABC008 for the treatment of inclusion body myosi

News

Boehringer preps phase 3 for dual-action obesity drug

Armed with results from a phase 2 trial, Boehringer Ingelheim has said it will take its obesity drug candidate survodutide into a phase 3 programme later this year.

News

UK sets aside £210m for antimicrobial resistance project

The UK Government has said it will provide £210 million in funding for a project that will track 'superbugs' in Africa and Asia, to curtail the threat posed by antimicrobi

News

Chiesi partners Aliada on brain-penetrating CNS therapies

Rare disease specialist Chiesi Pharma has forged an alliance with US biotech Aliada Therapeutics that will apply a technology designed to get drug molecules across the blo

News

UK clinical trials talent taskforce co-chairs

UK launches talent taskforce to tackle trials decline

Today saw the debut of a partnership between the UK NHS and an organisation that provides accreditation for clinical research professionals, aiming to attract, develop, an

Seagen posts breast cancer win ahead of Pfizer takeover

Abcuro raises $155m for KLRG1 drug trial

Boehringer preps phase 3 for dual-action obesity drug

UK sets aside £210m for antimicrobial resistance project

Chiesi partners Aliada on brain-penetrating CNS therapies

UK launches talent taskforce to tackle trials decline

FDA grants three priority vouchers to psychedelics

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks